PolarityTE — Investor Presentation (March 2018)
46 slides from PolarityTE's investor presentation, Mar 9, 2018
Slide 1: The Functional Polarization of Tissues: A Technology Platform Review
Slide 2: PolarityTE: where self regenerates self
Slide 3: Forward Looking Statements
Pa FORWARD LOOKING STATEMENTS bs This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warrants to the completeness of this information or, in the case of projections, as to their attainability or the accuracy and completenes
Slide 4: The Problem with Regenerative Medicine—is Tissue Engineering
The Problem with Regenerative Medicine—is Tissue Engineering Ask yourself Name one company or product that # truly regenerates ANYTHING?
Slide 5: Polarity: the asymmetric organization of cellular elements
po-lar-iety: the asymmetric organization of cellular elements, which allows development of specialized tissue and downstream function. Que 4.
Slide 6: The Tissue Engineering Triad
The Tissue Engineering Triad Overly Reductionist Approaches to Myopic Theories . —— sae en le Cell Suspension & Monolayer Cultures + Real Fun A cell, a molecule and/or scaffold has not and will not regenerate functionally-polarized, hierarchically organized tissue(s). Destruction of the intracellula
Slide 7: ©
©
Slide 8: The Solution to Regenerative Medicine
T he Solution to Regenerative Medicine Polarized Interfaces Drive Embryogenesis, Histogenesis and Tissue Regeneration {he tendency of living organ A Foc aleg nih gistinct ahteiozane preter ae tse ppermost and lowermost) ends, or to grow of orient ina particular direction. The functional polarization
Slide 9: PolarityTE - Welcome to the SHIFT
_PolarityTE™ - Welcome to the SHIFT™ EVOLVING TECHNOLOGY PLATFORMS AND PRODUCTS DP) We are a clinical stage, commercial biotechnology and regenerative materials company L978 with new and expanding technology platforms which are utilized to create functionally- \% polarized t tissues for ‘use in clin
Slide 10: SkinTE intended use
SkinTE™ is intended to be used by physicians or other appropriate healthcare providers for homologous uses of the skin and integumentary system. Patients who have suffered from an event, disease, process or who have an acquired defect that has resulted in the functional loss or absence of the skin a
Slide 11: PolarityTE Tackles the Regenerative Wound Care Market
PolarityTE Tackles the Rege tive Wound Care Market Current markets remain untapped with myopically-redundant and synthetic forms of tissue engineering products which do not utilize the functional and inherently regenerative tissues of the patient ‘Wound Prevalence Growth by Etiology Global markets f
Slide 12: SkinTE
| SkinTE™ inl] A Product for All Medical Providers Surgeons, Medical Doctors, Physician Assistants, Nurses, Wound Care Providers, Medics Patient Wounds Acute wounds, chronic wounds, acute burns, burn reconstruction, scar revision, surgical reconstruction, replacement of skin grafts Clinical Location
Slide 13: SkinTE video animation
Slide 14: Technology Platform
nology Platform support Platform 13:
Slide 15: Real-Time Assistant App
PolarityTE™ Real-Time Assistant App PolarityTE RTA Video Animation
Slide 16: A Proven Concept and an Evolving Tangible Technology
| A Proven Concept and an Evolving Tangible Technology EXPERIMENTAL! EXPERIMENTAL! Stimulation of the Follicular Bulge L DISCUSSION .GR6' Stem Cells with the Gut-Derived Transplantation of the LGR6* Epithelial Cell into Full-Thickness Cutaneous Wounds and Results in Enhanced Healing, N Human Alpha D
Slide 17: The Conventional Therapies and Fundamental Limitations
Slide 18: Current Therapies and their Fundamental Limitations
Current Therapies and their Fundamental Limitatio + Acellular scaffolds or matrices lack the innate ability to regenerate tissue and rely on surrounding tissue in-growth and ultimately secondary skin grafts for definitive coverage Allogeneic/Xenogeneic Cells: “ANTE he af a * Allogeneic (tissue or ce
Slide 19: Current Therapies and their Fundamental Limitations
Current Therapies and their Fundamental Limitations A Massive Market Saturated with Stagnant Products Lacking Skin TE Fundamental Principles and Building Blocks for True Functional Skin Regeneration Regenerative Cellular Regenerates Full Thickness Company Cellular Tissue Source Stem Cell Architectur
Slide 20: The Difference Simply Put—Skin Regenerates Skin
The a Difference Simply Put—Skin Regenerates Skin Native Embracing Complex Simplicity While other conventional regenerative medicine, cell therapy and tissue engineering companies and products try to reconstruct skin substitutes from a variety of cells, molecules, genes and scaffolds in order to cir
Slide 21: SkinTE Expands into Residual Scar Regions
SkinTE~ Expands into Residual Sear Regions ic: Comparing SkinTE to Native Wound Healing. (2.) Representative progression of wound healing in excised full-thickness burn wound (untreated control vs. excised full-thickness burn wound treated with SkinTE™. Image sequence ~ left column: ay 0; middle col
Slide 22: Comparing the Clinical Standard of Care to SkinTE
Comparing the Clinical Standard of Care to SkinTE™ Native Scar Healed Wound —_Native Skin Full-Thickness Allograft ‘Autograft|\\ margin Native Skin + Skin defects heal through a process of wound contraction and often scar formation. While skin grafts reduce contraction, patients still have scars. ‘S
Slide 23: SkinTE - Mid-Stage Intelligent and Dynamic Healing
| SkinTE™- Mid-Stage Intelligent and Dynamic Healing os TH age STE age ore Hae Native Healed and Contracted Wound ¢ < eo SkinTE™ Regenerative Healing “rena egoged en Mel Se Fert ‘Comparing Mid-stage Healing Processes Between Native Wounds and Defects Treated with SkinTE™. Stereoscopic Stereoscopic I
Slide 24: SkinTE - Early-Stage Healing Depicts Return of Pigment
SkinTE™- Early-Stage Healing Depicts Return of Pigment ‘SkinTE™ Treated Wound Bed & ROIs (2 Weeks Post-Op) Progressive early-stage Healing After application of skinTE™ to Pediatric Bum Patient Following Excision of standard of care, 2 ‘Spl-Thicness Skin Graft, 1oyeer-cld afican American male who suf
Slide 25: We Build Evolving Platforms, Not Just Products
PolarityTE™- We Build Evolving Platforms, Not Just Products re Our Technology Platforms oo Adipose’ The Core “TE” Products “TE" technology was discovered through careful observation and the study of neogenesis within systems, regenerative tissue healing and cellular propagation mechanisms in real-ti
Slide 26: The Core TE Advantage- Complex Simplicity Made Reality
The Core “TE” Advantage- Complex Simplicity Made Reality Autologous—From the Patient for the Patient: The immune system is highly complex and has evolved to recognize anything that is not truly “self.” Our foundational platform is built on using autologous tissue(s), avoiding allogeneic tissue rejec
Slide 27: Preclinical Development to Clinical Deployment
Preclinical Development Clinical Deployment Ex Vivo Optimization Prototype Modeling Studies Market Entry & Commercialization 2H2017, 2H 2017 2H2018 2H 2018 Development Pipeline of PdlartyTE Core “TE" Products. A pipeline chart depicting some of the public core “TE” tissue product candidates (defined
Slide 28: OsteoTE: Regeneration of Full-Thickness Bone Defects
OsteoTE™: Regeneration of Full-Thickness Bone Defects ntal be” ot A S37 ad o om Ves t a te ae CraniofacialSpine—Long Bone—Joints—Hand—De £
Slide 29: Craniofacial, Spine, Long Bone, Joints, Hand, Dental
24 Sfaniofatial=-Spifie) | ong Bone—oints—Hand—Dental_ > 4
Slide 30: Regeneration of Full-Thickness Bone Defects
Regeneration of Full-Thickness Bone Defects Pre-Defect Native | (ct) @ i) q " : rz uy ty Wwe | i Comparative Imaging of O:teoTE Substrate in Critical Sized Cranial Defect Model System. (2) Three dimensional (3-0) micro computed tomography (micro-CT) native cranial bone dsplaying pre-defect left pari
Slide 31: OsteoTE: Regeneration of Functional Polarized Bone
OsteoTE™: Regeneration of Functional Polarized Bone Native Defect > | OH? Woy h
Slide 32: OsteoTE: Combination with a Bone Allograft Vector
OsteoTE™: Combination with a Bone Allograft Vector Native Defect y @:
Slide 33: OsteoTE: Combination with a Dural Allograft Vector
OsteoTE™: Combination with a Dural Allograft Vector ry : Native Defect 29.
Slide 34: Comparative Autologous Bone Plate
Comparative Autologous Bone Plate Native
Slide 35: Demineralized Bone Matrix (DBM) +BMP2
Demineralized Bone Matrix (DBM) +BMP2 Native ‘ ak
Slide 36: Polarized Interfaces Drive Vascularized Osteogenesis
| Polarized Interfaces Drive Vascularized Osteogenesis Interfaces Drive Vascularized | Polarized Interfaces Drive Vascularized Osteogenesis Tit Profile Osteogenesis Profile OsteoTE DBM + BMP2
Slide 37: Not All Mineralization is the Same
t All Mineralization is the Same OsteoTE OsteoTE+BGAL0 — OsteoTE + DG! Autologous Bone Plate t 5 f OBB
Slide 38: Loading
Ing J ] man
Slide 39: Native Bone
C 3 S i <3) Native Bone OsteoTE Defect Control OsteoTE+ BGS OsteoTE + DGALO Auto Bone Plate DBM + BMP2 33;
Slide 40: Load vs Displacement
Load (N) Native Bone Auto Bone Flap OsteoTE +BG OsteoTE +DG OsteoTE 1 15 2 Displacement (mm) Defect Control DBM + BMP2
Slide 41: PolarityTE Growth- Public, Commercial, Scaling and Evolving
] PolarityTE™ Growth- Public, Commercial, Scaling and Evolving SkinTE™ Commercial Launch Triggered The PolarityTE™ Corporate Campus 2 Clinicalapplication initiated across.all wound types: * Chronic wounds, reconstructive wounds, acute burns, surgical wounds Sear revision: Removal of healed standard
Slide 42: The PolarityTEAM - Executive Management
The PolarityTEAM - Executive paiaarert Be ‘DenverLough,MD,PhD ‘Edward Swanson, MD John Stetson ‘Cameron Hoyler 1D. po Sse ae a mapa SShentareyatrrmime Nimo tienen ry Pole TE= pater Beever Toergneerg withers ; rupeting Spang LP see paralhh ca + MD Hermd Medal schol with ieesenet mth focuron ery tage
Slide 43: The PolarityTEAM - Board of Directors
The PolarityTEAM - Board of Directors a Oe Steve Gorlin Jon Mogford, PhD ¢ Director Director + Regenerative Medicine and Biotech Pioneer: + Vice Chancellor for Research, Texas A&M Management EET iependent Denver Lough, MD, PhD (Chairman & Chief Executive Officer Edward (Ned) Swanson, MD Executive Vi
Slide 44: The PolarityTEAM - Clinical Advisory Board
The PolarityTEAM - Clinical Advisory Board
Slide 45: We are PolarityTE - And Welcome to the SHIFT
We are PolarityTE™-And Welcome to the SHIFT™ PolarityTE™, Inc. (NASDAQ: COOL) The New Paradigm of Regenerative Medicine is Here And This Time it is Real with a Proven Platform Technology A Regenerative Medicine Company Like No Other A revolutionary and proprietary platform technology developing prod
Slide 46: PolarityTE Corporate
PolarityTE™ Corporate Website: www.PolarityTE.com Email: [email protected] Corporate Inquiries: (800) 378-2694 [email protected] NASDAQ Ticker: COOL 4 ;. PolarityTE™ Support ‘Customer Service: (800) 560-3983 [email protected] Medical Affairs: (800) 476-6057 Me